US 12,090,183

Application 17/822,677 · Granted Sep 17, 2024

Methods of treating solid or lymphatic tumors by combination therapy

Estimated expiration

March 9, 2037

10y 111d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Mar 9, 2017
+ 20 years
Mar 9, 2037
PTA +0d
Mar 9, 2037
TD cap (US 11,497,781)
Mar 9, 2037
Final
Mar 9, 2037

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
August 26, 2022
Earliest effective filing
March 9, 2017
Issue date
September 17, 2024
PTA
0 days
Base expiry (before PTA)
March 9, 2037

March 9, 2017 + 20 years = March 9, 2037

  • Continuation of application 16/083,709, filed Sep 10, 2018, issued as US 11,497,781
  • National stage entry of application PCTUS2017021694, filed Mar 9, 2017
  • National stage entry of application PCTUS2017021694, filed Mar 9, 2017
  • PRO62/306,470 — Provisional — not used for base term
  • PRO62/306,470 — Provisional — not used for base term
  • PRO62/306,470 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to March 9, 2037 (earliest expiring referenced patent: US 11,497,781)

  • US 11,497,781· Application 16/083,709Capping patent

    Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus cg0070 and an immune checkpoint inhibitor

    Filing date
    Sep 10, 2018
    Earliest effective filing
    Mar 9, 2017
    Issue date
    Nov 15, 2022
    PTA
    0 days
    Calculated expiration
    Mar 9, 2037

    National stage entry of PCTUS2017021694, filed Mar 9, 2017

    Mar 9, 2017 + 20y = Mar 9, 2037

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/822,677 · US 12,090,183

PatentReply compiles the prosecution history behind US 12,090,183: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12090183

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.